Urogen Pharma LtdNASDAQ:URGN
- LAST PRICE12.7000
- TODAY'S CHANGE (%)0.3200 (2.5848%)
- Bid / Lots12.2500/ 2
- Ask / Lots13.2700/ 1
- Open / Previous Close12.4900 / 12.3800
- Day Range
- 52 Week Range
- Volume254,463
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | URGN |
|---|---|---|
| 09:32 ET | 2028 | 12.49 |
| 09:34 ET | 500 | 12.59 |
| 09:38 ET | 688 | 12.54 |
| 09:41 ET | 1656 | 12.545 |
| 09:43 ET | 800 | 12.55 |
| 09:48 ET | 700 | 12.54 |
| 09:50 ET | 2000 | 12.51 |
| 09:52 ET | 300 | 12.515 |
| 09:54 ET | 100 | 12.5 |
| 09:56 ET | 500 | 12.5 |
| 10:03 ET | 200 | 12.44 |
| 10:10 ET | 700 | 12.44 |
| 10:12 ET | 100 | 12.43 |
| 10:17 ET | 300 | 12.48 |
| 10:21 ET | 100 | 12.49 |
| 10:24 ET | 100 | 12.47 |
| 10:26 ET | 200 | 12.445 |
| 10:28 ET | 200 | 12.445 |
| 10:30 ET | 100 | 12.43 |
| 10:32 ET | 407 | 12.449 |
| 10:33 ET | 100 | 12.45 |
| 10:35 ET | 1314 | 12.47 |
| 10:37 ET | 100 | 12.525 |
| 10:48 ET | 352 | 12.54 |
| 10:50 ET | 500 | 12.545 |
| 10:51 ET | 2100 | 12.55 |
| 10:53 ET | 1895 | 12.6 |
| 10:55 ET | 1200 | 12.5705 |
| 10:57 ET | 400 | 12.6 |
| 11:00 ET | 625 | 12.625 |
| 11:02 ET | 100 | 12.63 |
| 11:04 ET | 1978 | 12.63 |
| 11:06 ET | 1144 | 12.62 |
| 11:08 ET | 400 | 12.67 |
| 11:11 ET | 486 | 12.66 |
| 11:13 ET | 910 | 12.67 |
| 11:15 ET | 530 | 12.6799 |
| 11:18 ET | 200 | 12.62 |
| 11:22 ET | 323 | 12.61 |
| 11:24 ET | 1223 | 12.5519 |
| 11:31 ET | 1422 | 12.5993 |
| 11:36 ET | 400 | 12.57 |
| 11:38 ET | 200 | 12.585 |
| 11:44 ET | 200 | 12.6 |
| 11:45 ET | 300 | 12.6 |
| 11:47 ET | 100 | 12.59 |
| 11:56 ET | 900 | 12.58 |
| 12:03 ET | 700 | 12.63 |
| 12:07 ET | 850 | 12.63 |
| 12:09 ET | 100 | 12.61 |
| 12:12 ET | 186 | 12.64 |
| 12:18 ET | 900 | 12.65 |
| 12:27 ET | 300 | 12.6485 |
| 12:30 ET | 100 | 12.64 |
| 12:32 ET | 1201 | 12.6358 |
| 12:34 ET | 4000 | 12.665 |
| 12:36 ET | 1114 | 12.69 |
| 12:38 ET | 100 | 12.66 |
| 12:41 ET | 3100 | 12.67 |
| 12:43 ET | 500 | 12.68 |
| 12:45 ET | 1428 | 12.67 |
| 12:48 ET | 7311 | 12.705 |
| 12:50 ET | 200 | 12.735 |
| 12:56 ET | 1900 | 12.71 |
| 12:57 ET | 100 | 12.7 |
| 12:59 ET | 2000 | 12.71 |
| 01:06 ET | 125 | 12.68 |
| 01:08 ET | 5471 | 12.725 |
| 01:10 ET | 300 | 12.73 |
| 01:15 ET | 597 | 12.7169 |
| 01:17 ET | 400 | 12.725 |
| 01:19 ET | 716 | 12.73 |
| 01:21 ET | 8241 | 12.87 |
| 01:24 ET | 800 | 12.85 |
| 01:26 ET | 869 | 12.87 |
| 01:28 ET | 100 | 12.86 |
| 01:30 ET | 100 | 12.84 |
| 01:32 ET | 2120 | 12.815 |
| 01:33 ET | 2141 | 12.8 |
| 01:35 ET | 1100 | 12.83 |
| 01:37 ET | 100 | 12.84 |
| 01:39 ET | 549 | 12.83 |
| 01:42 ET | 500 | 12.85 |
| 01:44 ET | 200 | 12.85 |
| 01:46 ET | 100 | 12.82 |
| 01:48 ET | 100 | 12.835 |
| 01:51 ET | 674 | 12.815 |
| 01:53 ET | 900 | 12.77 |
| 01:55 ET | 422 | 12.77 |
| 01:57 ET | 700 | 12.82 |
| 02:00 ET | 1200 | 12.81 |
| 02:04 ET | 501 | 12.86 |
| 02:06 ET | 7000 | 12.88 |
| 02:08 ET | 330 | 12.845 |
| 02:09 ET | 2345 | 12.826 |
| 02:11 ET | 697 | 12.8 |
| 02:13 ET | 500 | 12.795 |
| 02:15 ET | 100 | 12.78 |
| 02:18 ET | 250 | 12.8099 |
| 02:20 ET | 100 | 12.795 |
| 02:22 ET | 2700 | 12.78 |
| 02:24 ET | 2290 | 12.78 |
| 02:27 ET | 3591 | 12.805 |
| 02:29 ET | 1100 | 12.808 |
| 02:31 ET | 900 | 12.77 |
| 02:33 ET | 200 | 12.76 |
| 02:36 ET | 200 | 12.755 |
| 02:40 ET | 100 | 12.75 |
| 02:42 ET | 258 | 12.75 |
| 02:44 ET | 100 | 12.75 |
| 02:45 ET | 1300 | 12.75 |
| 02:47 ET | 700 | 12.7466 |
| 02:49 ET | 400 | 12.755 |
| 02:51 ET | 200 | 12.74 |
| 02:54 ET | 699 | 12.75 |
| 02:56 ET | 818 | 12.73 |
| 03:00 ET | 200 | 12.74 |
| 03:02 ET | 2246 | 12.74 |
| 03:05 ET | 500 | 12.7338 |
| 03:07 ET | 1000 | 12.75 |
| 03:12 ET | 800 | 12.75 |
| 03:14 ET | 790 | 12.74 |
| 03:16 ET | 2432 | 12.7 |
| 03:18 ET | 3625 | 12.7 |
| 03:20 ET | 3000 | 12.76 |
| 03:21 ET | 200 | 12.77 |
| 03:23 ET | 200 | 12.745 |
| 03:25 ET | 675 | 12.75 |
| 03:27 ET | 100 | 12.73 |
| 03:30 ET | 200 | 12.74 |
| 03:32 ET | 100 | 12.735 |
| 03:34 ET | 400 | 12.7 |
| 03:36 ET | 584 | 12.73 |
| 03:38 ET | 200 | 12.72 |
| 03:39 ET | 2000 | 12.72 |
| 03:41 ET | 552 | 12.74 |
| 03:43 ET | 2897 | 12.74 |
| 03:45 ET | 400 | 12.73 |
| 03:48 ET | 857 | 12.7 |
| 03:52 ET | 4275 | 12.695 |
| 03:54 ET | 1900 | 12.66 |
| 03:56 ET | 2198 | 12.66 |
| 03:57 ET | 3229 | 12.64 |
| 03:59 ET | 33465 | 12.7 |
Yesterday
DJ UroGen Pharma Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 7:49AM ET on Thursday Oct 03, 2024 by Dow Jones
7:49AM ET on Thursday Oct 03, 2024 by Dow Jones
Oct 2, 2024
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer, from 8:00AM ET on Wednesday Oct 02, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 02, 2024 by Dow Jones
Sep 16, 2024
Sep 5, 2024
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 8:00AM ET on Thursday Sep 05, 2024 by Dow Jones
8:00AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Urogen Pharma Ltd | 521.4M | -3.9x | --- |
Y-mAbs Therapeutics Inc | 602.6M | -25.2x | --- |
Regenxbio Inc | 462.1M | -1.8x | --- |
SAGE Therapeutics Inc | 426.7M | -0.9x | --- |
Grail Inc | 390.3M | -0.1x | --- |
Alector Inc | 410.7M | -2.6x | --- |
Company Information
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Contact Information
- Headquarters
- 9 Ha'ta'asiya StRA'ANANA, Israel 4365007
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Arie Belldegrun
- President, Chief Executive Officer, Director
- Elizabeth Barrett
- Chief Financial Officer
- Dong Kim
- Chief Compliance Officer, General Counsel, Corporate Secretary
- Jason Smith
- Chief Commercial Officer
- David Lin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $521.4M |
|---|---|
Revenue (TTM) | $85.0M |
Shares Outstanding | 42.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.12 |
EPS | $-3.27 |
Book Value | $-2.01 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -93.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
